153171-22-3

Basic information

• Product Name: 2-(4-bromobenzyl)-1H-isoindole-1,3(2H)-dione
• Synonyms: 2-(4-bromobenzyl)-1H-isoindole-1,3(2H)-dione;2-(4-broMobenzyl)isoindoline-1,3-dione
• CAS NO: 153171-22-3
• Molecular Formula: C₁₅H₁₀BrNO₂
• Molecular Weight: 316
• Product Categories: alkyl bromide
• Mol File: 153171-22-3.mol
• Article Data: 12

Chemical Properties

• Melting Point: 133 °C
• Boiling Point: 445.7±28.0 °C(Predicted)
• Appearance: /
• Density: 1.604±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: -2.29±0.20(Predicted)
• CAS DataBase Reference: 2-(4-bromobenzyl)-1H-isoindole-1,3(2H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-bromobenzyl)-1H-isoindole-1,3(2H)-dione(153171-22-3)
• EPA Substance Registry System: 2-(4-bromobenzyl)-1H-isoindole-1,3(2H)-dione(153171-22-3)

Safety Data

• Hazardous Substances Data: 153171-22-3(Hazardous Substances Data)

Usage

General Description

2-(4-bromobenzyl)-1H-isoindole-1,3(2H)-dione is a chemical compound with a molecular formula C16H10BrNO2. It is a yellow solid that is commonly used in organic synthesis and medicinal chemistry research. 2-(4-bromobenzyl)-1H-isoindole-1,3(2H)-dione belongs to the isoindolinone class of chemicals and contains a bromobenzyl group. It has been studied for its potential biological activities, including its antimicrobial and antitumor properties. Additionally, it may be used as a building block for the synthesis of various pharmaceuticals and biologically active molecules. Overall, 2-(4-bromobenzyl)-1H-isoindole-1,3(2H)-dione is a versatile chemical that has applications in both research and industry.

Upstream product

• 85-44-9 phthalic anhydride 
• 26177-44-6 4-bromobenzylamine hydrochloride 
• 3959-07-7 4-Bromobenzylamine 
• 524-38-9 N-hydroxyphthalimide 
• 106-38-7 para-bromotoluene 
• 136918-14-4 phthalimide 
• 589-15-1 1-bromomethyl-4-bromobenzene 
• 1074-82-4 potassium phtalimide 
• 873-75-6 4-bromobenzenemethanol 

Downstream Products

• 1001242-92-7 2-(4-morpholin-4-ylbenzyl)-1H-isoindole-1,3(2H)-dione 
• 51980-05-3 4-allylbenzonitrile 
• 1122-91-4 4-bromo-benzaldehyde 
• 623-00-7 4-bromobenzenecarbonitrile 
• 10602-01-4 p-bromobenzaldehyde 1,3-dioxolane 
• 1222368-50-4 6-bromo-3-methyl-isoquinoline 
• 68819-84-1 tert-butyl N-(4-bromobenzyl)carbamate 
• 1616590-38-5 (E)-3-[4-(4,4-dimethyl-3,4-dihydrocarbostyril-6-carbonyl)aminomethylphenyl]acrylic acid ethyl ester 
• 1616590-16-9 (4,4-dimethyl-3,4-dihydrocarbostyril)-6-carboxylic acid (E)-4-[2-(hydroxycarbamoyl)vinyl]benzylamide 
• 383665-96-1 (E)-3-[4-(tert-butoxycarbonylaminomethyl)phenyl]acrylic acid ethyl ester 
• 905456-93-1 C₄₁H₂₉N₅O₂ 
• 90561-76-5 N-(4-bromo-benzyl)-acetamide 
• 132273-07-5 2-(p-bromobenzyl)-1,1,3,3-tetramethyl-1,3-disilaisoindoline 
• 3959-07-7 4-Bromobenzylamine 

Relevant articles and documents

Five-membered heteroaromatic derivative, preparation method and application thereof

The invention belongs to the technical field of medicines, and particularly relates to a five-membered heteroaromatic compound, a composition, a preparation method and application thereof. The compound or the composition can be used as an inhibitor of a retinoid-related orphan receptor [gamma]t (ROR [gamma]t). The invention also relates to a method for preparing the compound and the composition, and application of the compound and the composition in treatment or prevention of ROR [gamma]t-mediated cancers, inflammations or autoimmune diseases of mammals, especially human beings.

Alkoxide-Catalyzed Hydrosilylation of Cyclic Imides to Isoquinolines via Tandem Reduction and Rearrangement

An alkoxide-catalyzed hydrosilylation of cyclic imides to isoquinolines was realized via tandem reduction and rearrangement. Using TMSOK as the catalyst and (EtO)2MeSiH as the reductant, a series of cyclic imides containing different functional groups were reduced to the corresponding 3-aryl isoquinolines in moderate to good yields. The scenario of the reaction pathway was supposed to involve the reduction of imides to ω-hydroxylactams, which underwent rearrangement in the presence of a base catalyst, and then the carbonyl reduction, followed by siloxy elimination.

THERAPEUTIC INHIBITORY COMPOUNDS

The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.